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Aims Cardiometabolic diseases (hypertension, coronary artery disease [CAD] and diabetes are known to associate with
poorer cognitive ability but there are limited data on whether having more than one of these conditions is associ-
ated with additive effects. We aimed to quantify the magnitude of their associations with non-demented cognitive
abilities and determine the extent to which these associations were additive.
...................................................................................................................................................................................................
Methods and
results
We examined cognitive test scores in domains of reasoning, information processing speed and memory, included as
part of the baseline UK Biobank cohort assessment (N¼ 474 129 with relevant data), adjusting for a range of poten-
tially confounding variables. The presence of hypertension, CAD and diabetes generally associated with poorer cogni-
tive scores on all tests, compared with a control group that reported none of these diseases. There was evidence of
an additive deleterious dose effect of an increasing number of cardiometabolic diseases, for reasoning scores (unstan-
dardized additive dose beta per disease¼0.052 score points out of 13, 95% CI [confidence intervals] 0.063
to 0.041, P< 0.001), log reaction time scores (exponentiated beta¼ 1.005, i.e. 0.5% slower, 95% CI 1.004–1.005,
P< 0.001) and log memory errors (exponentiated beta¼ 1.005 i.e. 0.5% more errors; 95% CI 1.003–1.008).
...................................................................................................................................................................................................
Conclusion Cardiometabolic diseases are associated with worse cognitive abilities, and the potential effect of an increasing
number of cardiometabolic conditions appears additive. These results reinforce the notion that preventing or
delaying cardiovascular disease or diabetes may delay cognitive decline and possible dementia.
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Introduction
Background
Cognitive decline impacts adversely on the quality of life of affected
individuals and their families and can impair adherence to treatment
of comorbid conditions.1,2 Anecdotally, individuals worry more
about cognitive decline and dementia than any other condition as
they age.3 Therefore, there is substantial interest in identifying modifi-
able risk factors to ameliorate cognitive decline.4,5
Individual cardiometabolic diseases such as hypertension, coronary
artery disease (CAD) and diabetes have been shown to associate
with impaired cognitive function in cross-sectional studies.6–8
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Cardiometabolic conditions and cognitive decline may simply share
common risk factors or the association may be causal. Impaired car-
diovascular function may cause cognitive decline by inhibiting cere-
brovascular blood flow (called ‘neurovascular coupling’9) possibly
leading to hypoperfusion and the amyloid beta plaques that charac-
terize Alzheimer’s disease (AD).9,10 Some authors have suggested
that the association may reflect reverse causation due to people with
poorer cognitive function being less likely to adopt health-promoting
lifestyles.2,11 While this may be the case, longitudinal data have also
shown cardiometabolic diseases to be associated with subsequent
decline in cognition over time.8 While it is established that individual
cardiometabolic diseases are associated with non-demented cogni-
tive ability,12 it is unknown whether there is an additive effect from
having more than one disease.
UK Biobank is a very large, general population cohort that re-
cruited participants in middle to older-age, prior to the onset of frank
dementia. The data collected at baseline included cognitive function
tests and prevalent cardiometabolic disease as well as relevant con-
founders including mood disorder which has not been available in
many previous studies. The current study aims to determine whether
there is evidence of a potential additive effect of three cardiometa-
bolic diseases: diabetes hypertension and myocardial infarction/an-
gina (the latter two herein referred to as CAD) on cognitive
outcomes in the UK Biobank cohort. This is an important question
since there is a rising number surviving with CAD and, as obesity lev-
els rise, more are also developing and living longer with diabetes.
Methods
Materials and procedure
We examined three tests that were included as part of the UK Biobank
baseline cognitive assessment. The complete battery is detailed in an open-
access baseline paper.13 The first of these was a task with thirteen logic/
reasoning-type questions and a two-minute time labelled fluid intelligence
in the UK Biobank protocol but hereafter referred to as verbal-numerical
reasoning (http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id¼20016). The
maximum score was 13. The Cronbach alpha coefficient for these items
has been reported elsewhere as 0.62,14 and the task shows reasonable reli-
ability across on average 4.3 years in 4253 participants with repeat data
(r¼ 0.65, P<0.001). The next task was a visual memory test called pairs
matching (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id¼100030), where
participants were asked to memorize the positions of six card pairs, and
then match them from memory while making as few errors as possible.
We refer to this test as the memory task from here on. Scores on the
memory test are for the number of errors that each participant made, and
higher scores are, therefore, worse. The memory test did not show good
reliability in 19 017 participants with longitudinal data (r¼ 0.16, P<0.001);
however, this may partly be due to slight floor effects where most partici-
pants made few-to-no errors on repeat assessment, and it will be a more
informative test variable when measured at baseline. Finally, participants
completed a timed test, measured in milliseconds, of symbol matching;
similar to the common card game Snap (http://biobank.ctsu.ox.ac.uk/crys
tal/field.cgi?id¼20023) which we refer to as reaction time. The reaction
time task has been shown to have acceptable test–retest reliability over a
mean interval of 4.3 years (r¼ 0.54, P<0.001) in 19 327 participants who
underwent repeat assessment. The reasoning task was added to the partici-
pant assessment part-way through the baseline assessment phase and sam-
ple sizes for the tasks, therefore, vary.
As part of the baseline assessment, participants were asked whether a
physician had diagnosed myocardial infarction, angina, stroke, hypertension
or diabetes. We defined CAD as angina and/or myocardial infarction.
Participants self-reported other conditions freely on a separate assess-
ment screen (e.g. atrial fibrillation). Townsend deprivation indices were
derived from postcode of residence.15 They provide an area-based meas-
ure of socioeconomic deprivation derived from aggregated data on car
ownership, household overcrowding, owner-occupation and unemploy-
ment. Education was based on self-report of the highest qualification
achieved and dichotomised into university/college degree or less. (We
have conducted additional analysis and found that analysing the ‘education’
variable as a more fine-grained ordinal variable of ‘degree; A-levels/AS-lev-
els; O-levels/GCSEs; CSEs; NVQ/HND/HNC; none’ made no difference
to the final results; data available upon request.) Participants self-reported
their ethnic group and we recoded this into white and non-white.16 Body
mass index was measured by trained research staff. Participants removed
their shoes and heavy outer clothing. Weight was measured, to the near-
est 0.1 kg, using a Tanita BC-418 MA body composition analyser and
height using a Seca 202 height measure. Body mass index (BMI) was
derived from: weight (kg)/(height (m)  height (m)). Smoking was coded
as never, previous, or current smoker based on self-report. Frequency of
alcohol intake was recorded as never, special occasions only, 1–3 times
per month, 1–2 times per week, 3–4 times per week, daily/almost daily.
Participants self-reported whether they were on medication for choles-
terol, high blood pressure or on insulin. The minority of participants that
did not know or chose not to answer were removed.
Analyses
We excluded participants who declined to provide data on cardiometa-
bolic diseases at baseline, as well as participants who reported chronic
neurological diseases that could directly affect cognitive function; such as
dementia or stroke (see Supplementary material online, Table S1). We
also excluded participants outside the formal UK Biobank age range of
40–70 years. The remaining participants were classified into mutually ex-
clusive categories according to the number and type of cardiometabolic
diseases they reported, including a common comparison group compris-
ing participants with none of the cardiometabolic diseases.
The cognitive tests were treated as outcome variables in a series of lin-
ear regression models. Cognitive data that were not normally distributed
were transformed using STATA v.13,17 which was used for all analyses.
We applied a natural log transformation to the reaction time scores
which were positively skewed and used the LNþ 1 function to transform
the pairs-matching error scores which were significantly zero-inflated and
positively skewed. After these adjustments, all outcome variables were
normally distributed individually and when adjusted for covariates; in any
case the final results were similar when the data were re-analysed using
non-parametric equivalent tests as a check.
First, we undertook a series of sub-group analyses, comparing partici-
pants in each of the disease categories with the common comparison
group of no cardiometabolic disease. We then entered all participants in a
single model in which the number of eligible cardiometabolic diseases was
entered as a numerical variable (ranging 0–3). Each of these models was
run: a base model (adjusted for age in years, sex and white/non-white eth-
nicity); a partially adjusted model (also adjusted for Townsend score, edu-
cation and depression); and fully adjusted (also adjusted for smoking
status, alcohol intake, cholesterol/BP/insulin medication use and BMI). The
results are reported as unstandardized beta coefficients for reasoning
scores and exponentiated beta coefficients for the log transformed mem-
ory and reaction time data, because the latter are easier to interpret. For
example, an exponentiated beta coefficient of 1.00 would equate to no dif-
ference and 1.01 would equate to a 1% increase in reaction time. Because
2 D.M. Lyall et al.
of the large sample size we elected to use P<0.001 as nominal significance.
This P value is conservative also to partly offset the risk of multiple com-
parisons. We also report the variance explained by each model (r2).
As additional analyses, we also ran a more typical single multivariate
model testing for associations where reported CAD, diabetes and hyper-
tension were not in mutually exclusive groups; i.e. someone could be in
all three groups. These results were very similar to our reported findings
and are not shown but available upon request. With regard to collinear-
ity, variance inflation factors for variables in the final models were accept-
able (range¼ 1.02–1.54).18
Results
Of the 502 649 UK Biobank participants 22 221 (4.4%) reported a
neurological illness and were excluded, leaving 480 428 participants.
Of those, 478 567 (99.6%) provided relevant cardiometabolic disease
information. We removed 10 participants that were outside the for-
mal UK Biobank age range of 40–70 years, as they inflated the age/
cognitive score error bars. This left 478 557 participants, who had a
mean age of 56.44 years (SD¼ 8.10), and of which 216 758 were
male (45.3%), 422 210 were of white origin (88.5%) and 318 464
(32.8%) had a degree. In terms of depression, 18 249 self-reported
history of this disease (3.8%). Descriptive statistics split by cardiome-
tabolic group are shown in Table 1. There were 474 129 participants
with reaction time data, 437 765 with memory data and 158 631 with
reasoning data (the latter having been added part-way through
assessment).
Reasoning
In the base model, participants with cardiometabolic disease had
poorer reasoning scores than those without (Table 2). The unstan-
dardized beta coefficients ranged from 0.207 to 0.835 and all
were statistically significant. Adjustment for potential confounders
attenuated the associations. The variance explained by each model
was r2¼ 0.06 i.e. 6%, (base), 0.15 (partial) and 0.16 (full). All but three
associations remained statistically significant at P<0.001.
Reaction time
Participants with cardiometabolic diseases had longer response times
than those without. All the associations were statistically significant in
the base model, with the exponentiated beta coefficients ranging
from 1.009 to 1.045 (i.e. 0.9–4.5% slowing). Adjustment attenuated
the coefficients and all but three remained statistically significant
(Table 3). The variance explained by each model was r2¼ 0.11 i.e.
11%, (base), 0.12 (partial) and 0.12 (full).
Visual memory
In the base model, isolated CAD, as well as diabetes plus hyperten-
sion were associated with significantly more memory errors vs. the
control group (Table 4). Following full adjustment for potential con-
founders, these associations were significant plus that of hypertension
plus CAD. The variance explained by each model was r2¼0.03 i.e.
3% (base), 0.03 (partial) and 0.03 (full).
Dose effect of disease number
In the fully adjusted model, there were clear and statistically
significant dose relationships between the number of
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and log reaction time scores. As the number of diseases increased
from 0 to 3, reasoning scores significantly fell while log reaction time
and log memory errors significantly increased (i.e. got worse;
Table 5).
Additional analyses
We re-ran all analyses having excluded 2283 participants with self-
reported atrial fibrillation. This did not affect any of the final results.
We additionally tested for interaction between dose increase in num-
ber of diseases (0;1;2;3), and sex on cognitive scores. The interaction
terms for log memory errors (P¼ 0.025) and log reaction time
(P¼ 0.828) did not attain statistical significance at our threshold of
0.001. There was a borderline non-significant interaction (based on
our conservative alpha of 0.001) between gender and increasing dis-
eases on reasoning scores (interaction b¼0.036, 95% CI¼0.059
to 0.012, P¼ 0.003), where males showed a slightly larger effect of
disease count (beta¼0.049 vs. 0.034; see Supplementary mater
ial online, Table S2).
We tested for interaction between decade of age (40–50; 51–60;
61–70) and disease number on cognitive outcomes. There was a
statistically significant interaction between age decile and disease
number on log reaction time (interaction exponentiated
beta¼ 0.9990, 95% CI 0.99984–0.99995, P<0.001) where younger
participants showed a slightly larger effect of increasing cardiometa-
bolic diseases (e.g. exponentiated beta in 40–50 age group¼1.009,
95% CI¼ 1.007–1.010, P<0.001), compared with older partici-
pants (e.g. 61–70 age group exponentiated beta¼1.005, 95%
CI¼ 1.004–1.005, P<0.001). There were no significant interactions
for log memory errors (P¼ 0.090) and reasoning (P¼ 0.813). Table
S2 shows the effects of increasing disease count, split by sex and
also decade of age.
..................................................... ..................................................... .....................................................
....................................................................................................................................................................................................................
Table 2 Reasoning and cardiometabolic diseases
Base modela Partially adjustedb Fully adjustedc
Beta
coefficient
95% CI P value Beta
coefficient
95% CI P value Beta
coefficient
95% CI P value
Hypertension only 0.396 0.473 0.319 <0.001 0.300 0.374 0.226 <0.001 0.183 0.258 0.108 <0.001
CAD only 0.207 0.233 0.181 <0.001 0.123 0.148 0.098 <0.001 0.107 0.135 0.079 <0.001
Diabetes only 0.491 0.572 0.410 <0.001 0.336 0.413 0.259 <0.001 0.270 0.348 0.192 <0.001
CAD & diabetes 0.835 1.055 0.615 <0.001 0.608 0.819 0.398 <0.001 0.431 0.643 0.218 <0.001
Hypertension & diabetes 0.510 0.592 0.427 <0.001 0.313 0.392 0.234 <0.001 0.248 0.328 0.169 <0.001
Hypertension & CAD 0.403 0.467 0.339 <0.001 0.240 0.302 0.179 <0.001 0.151 0.215 0.087 <0.001
Hypertension, CAD & diabetes 0.687 0.833 0.542 <0.001 0.444 0.583 0.305 <0.001 0.287 0.429 0.146 <0.001
Beta values reflect the difference vs. healthy controls; groups are mutually exclusive so no participant is in more than one.
CI, confidence interval; CAD, coronary artery disease.
aAdjusted for age, sex and ethnicity.
bAdjusted for age, sex, ethnicity, Townsend score, depression and education.
cAdditionally adjusted for smoking status, alcohol intake, medication use and body mass index.
..................................................... ..................................................... .....................................................
....................................................................................................................................................................................................................
Table 3 Log reaction time and cardiometabolic diseases
Base modela Partially adjustedb Fully adjustedc
Beta
coefficientd
95% CI P value Beta
coefficientd
95% CI P value Beta
coefficientd
95% CI P value
Hypertension only 1.030 1.026 1.034 <0.001 1.027 1.023 1.031 <0.001 1.021 1.016 1.025 <0.001
CAD only 1.009 1.008 1.010 <0.001 1.007 1.005 1.008 <0.001 1.005 1.004 1.007 <0.001
Diabetes only 1.016 1.012 1.020 <0.001 1.012 1.008 1.016 <0.001 1.008 1.004 1.012 <0.001
CAD & diabetes 1.045 1.034 1.056 <0.001 1.038 1.027 1.049 <0.001 1.029 1.018 1.040 <0.001
Hypertension & diabetes 1.022 1.018 1.026 <0.001 1.017 1.013 1.021 <0.001 1.013 1.009 1.017 <0.001
Hypertension & CAD 1.031 1.027 1.034 <0.001 1.027 1.024 1.030 <0.001 1.022 1.018 1.025 <0.001
Hypertension, CAD & diabetes 1.042 1.035 1.049 <0.001 1.035 1.028 1.042 <0.001 1.029 1.021 1.036 <0.001
Beta values reflect the difference vs. healthy controls. CI, confidence interval; CAD, coronary artery disease.
aAdjusted for age, sex and ethnicity.
bAdjusted for age, sex, ethnicity, Townsend score, depression and education.
cAdditionally adjusted for smoking status, alcohol intake, medication use and body mass index.
dExponentiated.
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Interpretation
In this large, general population study, the association between cardio-
metabolic disease and poor cognitive function (specifically processing
and reasoning domains) extended beyond diabetes to other diseases
of hypertension and CAD. Furthermore, there was a clear relationship
whereby the potential impact was greater among those with more
than one cardiometabolic disease. The association with cardiometa-
bolic disease count was broadly linearly additive for reasoning scores
and log memory errors, and potentially multiplicative for log reaction
time slowing. The negative association with these cognitive measures
was independent of age, gender, ethnicity, socioeconomic status, edu-
cational level, adverse lifestyle risk factors and comorbid depression.
In our study, the magnitude of the effect was modest yet significant;
for example having CAD plus diabetes resulted in a 0.8 decrement in
reasoning scores out of a maximum score of 13. However, given that
average ages of participants in different groups were around 50s to
early 60s, these findings are nevertheless important and herald further
worsening of cognitive function as mostly middle-aged individuals with
exposure to multi-morbidity age.8,19 In clinical terms, our results pro-
vide encouragement over the potential to limit cognitive decline by
better prevention or delaying of cardiometabolic diseases. Incident de-
mentia rates have dropped by 20% in the last two decades, and this
may be due to better cardiovascular management.20
Previous studies have shown than cardiometabolic diseases are
associated with poorer cognitive performance, but this is the first
demonstration of an additive effect of disease count so far as any of
the authors are aware. Demonstrating that the direction of the asso-
ciation is from cardiometabolic disease to cognition is supported by
the current findings, although it does not exclude the possibility that
worse cognitive performance may confer risk of cardiometabolic dis-
ease through lifestyle behaviours.2,11 It is interesting that our findings
are mostly significant even after correction for smoking, alcohol in-
take and BMI, as these lifestyle factors may be expected to explain
part of the association between cognitive ability and cardiometabolic
.......................................................... ........................................................... ...........................................................
.......................................................... ........................................................... ...........................................................
....................................................................................................................................................................................................................
Table 5 Cognitive abilities and cardiometabolic disease count
Reasoning scores Log reaction time Log memory errors
95% confidence intervals 95% confidence intervals 95% confidence intervals
Beta
coefficient
Lower Upper P value Beta
coefficienta
Lower Upper P value Beta
coefficienta
Lower Upper P value
One disease 0.125 0.152 0.098 <0.001 1.006 1.005 1.008 <0.001 1.014 1.009 1.020 <0.001
Two diseases 0.200 0.251 0.149 <0.001 1.019 1.016 1.022 <0.001 1.022 1.011 1.033 <0.001
Three diseases 0.288 0.043 0.147 <0.001 1.029 1.021 1.036 <0.001 1.027 0.998 1.057 0.071
Additive dose effect 0.052 0.063 0.041 <0.001 1.005 1.004 1.005 <0.001 1.006 1.003 1.008 <0.001
Beta values reflect the difference vs. healthy controls; except for the ‘additive dose effect’ beta which shows the linear effect of having zero to three diseases. All associations
are adjusted for age, gender, ethnicity, Townsend deprivation scores, depression, education, smoking intake, alcohol, medication for insulin/hypertension/cholesterol and BMI
(‘fully adjusted model’). The beta coefficients for one/two/three disease groups use the no disease (control) group as referent.
aBetas for log reaction time and memory errors are exponentiated.
..................................................... ..................................................... .....................................................
....................................................................................................................................................................................................................
Table 4 Log memory error scores and cardiometabolic diseases
Base modela Partially adjustedb Fully adjustedc
Beta
coefficientd
95% CI P value Beta
coefficientd
95% CI P value Beta
coefficientd
95% CI P value
Hypertension only 1.013 0.996 1.029 0.129 1.004 0.988 1.021 0.607 1.009 0.993 1.026 0.277
CAD only 1.015 1.010 1.021 <0.001 1.010 1.005 1.015 <0.001 1.017 1.011 1.023 <0.001
Diabetes only 0.999 0.983 1.014 0.853 0.988 0.973 1.004 0.140 0.988 0.972 1.004 0.141
CAD & diabetes 1.008 0.965 1.053 0.715 0.996 0.954 1.041 0.874 0.994 0.951 1.040 0.801
Hypertension & diabetes 1.032 1.015 1.048 <0.001 1.021 1.004 1.037 0.012 1.031 1.014 1.048 <0.001
Hypertension & CAD 1.014 1.000 1.027 0.043 1.002 0.989 1.016 0.727 1.019 1.005 1.033 0.007
Hypertension, CAD & diabetes 1.022 0.993 1.051 0.134 1.009 0.980 1.038 0.549 1.027 0.998 1.057 0.073
Beta values reflect the difference vs. healthy controls. CI, confidence interval; CAD, coronary artery disease.
aAdjusted for age, sex, and ethnicity.
bAdjusted for age, sex, ethnicity, Townsend score, depression and education.
cAdditionally adjusted for smoking status, alcohol intake, medication use and body mass index.
dExponentiated.
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disease. Clinically, the recognition of dementia into older age can be
somewhat weighted towards decline in memory, and this may lead to
under-recognition of cognitive disorders in cardiovascular disorders.
Lack of statistical power is a common problem when undertaking
sub-groups analyses. UK Biobank is very large; with around 500 000
participants. Therefore, in spite of being a general population cohort
recruited in middle-age the numbers in each sub-group were higher
than achieved in the majority of individual studies. The smallest sub-
group was 1120 participants with CAD plus diabetes.
Limitations
The UK Biobank participants are representative of the general popu-
lation in terms of breakdown by age, sex, ethnicity and deprivation.
However, as with all general population cohort studies, they are likely
to be unrepresentative in terms of the prevalence of lifestyle risk fac-
tors and disease. A causal relationship between cardiometabolic dis-
ease and cognitive decline is plausible. However, both causation and
reverse causation have been postulated. All effect sizes attenuated
somewhat from the base models when adjusted for factors like de-
privation, lower education and smoking behaviour, reflecting a de-
gree of confounding (which we have attempted to control for
statistically). Cardiometabolic disease may impact adversely on cere-
brovascular blood flow and, therefore, cognitive function.
Alternatively people with worse mental ability may be less likely to
engage in healthy behaviours that protect against cardiometabolic
disease.2,9 In a cross-sectional study, it is not possible to establish the
temporal relationship between cardiometabolic disease and cognitive
decline and, therefore, the direction of causation; the same limitation
is also often true for prospective studies. UK Biobank does not have
a measure of lifetime intelligence from before the onset of major car-
diometabolic pathology and, therefore, cannot extrapolate the rela-
tive contributions of these. A recent study which included data from
UK Biobank showed that presence of two or three cardiometabolic
diseases (in this case diabetes, myocardial infarction or stroke) was
associated with earlier and more prevalent mortality, and our findings
may be affected by a degree of prodromal physical decline in those
people.21
We did not correct for type-1 error in our findings e.g. with
Bonferroni or False Discovery Rate corrections,22 because our
P value was set very conservatively at P<0.001. However, the very
large sample size is such that type-1 error is a still possibility in our
findings. Focussing on the effect sizes, the differences between groups
were often modest, however, are nevertheless important.
Participants stated whether their doctor had diagnosed them with
various individual cardiometabolic diseases; however, we are unable
to verify these—however, recent evidence in UK Biobank shows that
self-reported illnesses generally tally with self-reported medica-
tions.23 If these diagnoses were in some way over or under-reported,
this misclassification may slightly attenuate or strengthen the associ-
ation with cognitive test scores.
We adjusted for socioeconomic deprivation with the Townsend
index. This gives an area-based average of deprivation rather than an
individual-level detailed metric of social deprivation but is neverthe-
less a robust indicator of risk. There were differences between
groups in terms of age (range 55–62). We controlled for this statistic-
ally, however, covarying for age in years may not completely capture
age-related differences.
We found somewhat inconsistent results with the memory errors
score, e.g. where the linear disease number effect was significant, but
the effect of having diabetes plus CAD plus hypertension vs. no dis-
eases, was not. The effect sizes were relatively small. None of the
cognitive tests not been externally validated with more widely used
tasks of fluid intelligence, and it is unclear how sensitively they meas-
ure cognitive impairment. Our findings with the memory test may re-
flect a degree of type-1 error.
Future research
The current study used only the baseline data from UK Biobank and
was, therefore, cross-sectional in nature, albeit of a scale rarely seen.
All participants are currently undergoing repeat cognitive testing
(assuming they choose to attend) as part of an MRI assessment, and
are being followed-up via linkage to record linkage to routine clinical
records.24,25 Therefore, future studies could investigate the associ-
ation between baseline cardiometabolic disease and cognitive decline
over time as well as the association between cognitive impairment
and long-term cardiometabolic and other outcomes.
Summary
Among 474 129 participants in UK Biobank, cardiometabolic diseases
(diabetes hypertension and CAD) were associated with poorer cog-
nitive function in relation to reasoning, information processing speed and
(less convincingly) memory. These associations were generally inde-
pendent of potential confounders. In addition to each disease having
independent associations, there were dose relationships whereby
having more than one cardiometabolic disease was associated with
greater impairments in the cognitive domains of reasoning and pro-
cessing speed. Our findings highlight the potential importance for
cognitive health of both primary prevention of individual cardiometa-
bolic diseases (i.e. preventing or delaying cardiovascular pathology)
and secondary prevention among people with one condition who
are at risk of developing a comorbid disease. Given rising levels of
multi-morbidity and public health concerns regarding rising levels of
cognitive decline, our work has important implications for future re-
search in this important area.
Supplementary material
Supplementary material is available at European Heart Journal online.
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